NCT00495378 2016-12-20
RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia
Ortho Biotech Products, L.P.
Phase 4 Terminated
Clinical Trials
6 trialsNCT00267007 2014-06-04
A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated
NCT00386152 2013-07-19
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated
NCT00210730 2011-06-10
The Duration Study
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00350090 2011-05-19
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00083434 2011-04-27
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated